drugset / Trial / NCT06024057
An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA
Not yet recruiting
3 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the scaling clinical trail of AAV2-RPE65 gene therapy agent (LX101) in patients with congenital amaurosis (LCA).
Timeline
- Start
- 2023-09-01
- Primary completion
- 2028-09-30
- Completion
- 2038-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LX101 | Gene therapy (AAV / viral vector) | 0.3 ml | Other |